GlaxoSmithKline (GSK) CEO, Emma Walmsley, Named InstinctBusiness CEO of the Week

Emma Walmsley, CEO of GlaxoSmithKline (GSK), has been named CEO of the Week, recognizing her outstanding leadership and transformative impact within the pharmaceutical industry.

Since 2017, Walmsley has led GSK, a global pharmaceutical and biotechnology leader, making history as the first woman to lead a major global pharmaceutical company. Under her leadership, GSK has undergone a significant strategic transformation, focusing on biopharmaceutical innovation, vaccine development, and consumer healthcare growth.

Born in the United Kingdom in 1969, Walmsley earned a degree in Classics and Modern Languages from Oxford University. Her career began at L’Oréal, where she spent 17 years in senior leadership roles across Europe and Asia before transitioning to GSK in 2010 as President of Consumer Healthcare. She later played a pivotal role in the GSK-Novartis joint venture, one of the world’s largest consumer health partnerships.

As CEO, Walmsley has redefined GSK’s strategic direction, emphasizing R&D investment in oncology and infectious diseases. She spearheaded the $13 billion acquisition of Novartis’ 36% stake in GSK Consumer Health, further solidifying the company’s leadership in the sector. In 2022, she oversaw the demerger of Haleon, enabling GSK to sharpen its focus on pharmaceuticals and vaccines.

A visionary leader, Walmsley was appointed Dame Commander of the British Empire (DBE) in 2020, for her contributions to business and healthcare, and has received numerous accolades.

This recognition, from InstinctBusiness Magazine, celebrates top-performing executives globally, celebrating exceptional leadership, innovation, and impact across diverse industries.